Design Therapeutics

📍 Carlsbad, United States🗓 Founded 2017👥 66 employees💰 Last funded Jun 2021
Biotechnology Research🌐 designtx.com
Website LinkedIn
We are a clinical-stage biotechnology company developing a new class of therapies based on its platform of GeneTAC™ gene targeted chimera small molecules. The company’s GeneTAC™ molecules are designed to either dial up or dial down the expression of a specific disease-causing gene to address the underlying cause of disease. Design’s lead program is focused on the treatment of Friedreich ataxia, followed by programs in Fuchs endothelial corneal dystrophy and myotonic dystrophy type-1 and discovery efforts for multiple other serious degenerative disorders caused by nucleotide repeat expansions. For more information, please visit designtx.com.
2
Total investors
0
Early stage
2
Mid stage
0
Late stage
2017
Founded

Investors

2 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
2
Frequently asked questions
Who invested in Design Therapeutics?
Design Therapeutics has 2 investors on record on gritt.io, 2 mid-stage.
When did Design Therapeutics last raise funding?
The most recent investment in Design Therapeutics recorded on gritt.io was in June 2021.
When was Design Therapeutics founded?
Design Therapeutics was founded in 2017.
What industry is Design Therapeutics in?
Design Therapeutics operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Design Therapeutics based?
Design Therapeutics is headquartered in Carlsbad, United States.